Science in our DNA
At AstraZeneca, science is at the core of everything we do. But more than that, science is who we are.
It takes a special commitment to keep pushing the boundaries. To keep believing. To never give up.
"DNA repair represents an Achilles’ heel of cancer. My hope is that we at AstraZeneca can help solve this using our portfolio of DNA damage response agents in order to benefit patients."
Leading scientific expertise
We combine a unique range of knowledge, skills and experience with a passion for following the science. Here are some examples of our key capabilities.
Our scientific heritage is grounded in pushing the boundaries of small molecule discovery and development. For decades, our scientists have led the way in identifying the right chemical leads. Our early discovery and high throughput screening capabilities enable us to screen thousands of compounds a day to identify molecules with potential to inhibit or activate the target.
Biologics are in development across all our therapy areas and now account for half our pipeline. Much of our biologics work focuses on specifically defined or biologically targeted populations, determined by the scientific pathway of the disease and mode of action of the molecule. Biologics have revolutionised medicine, treating complex diseases including various types of cancer and autoimmune disorders.
We aim to provide industry-leading devices that are easy to use and improve the lives of patients. This includes smart technology-enabled devices that improve patient outcomes through intelligent solutions such as patient feedback to support correct use, dose reminders and disease progression and monitoring. Along with inhalation devices we are also exploring how to better meet patient needs in non-oral, non-inhaled therapies across our main therapy areas.
Immuno-oncology is a promising therapeutic approach that harnesses the patient’s own immune system to help fight cancer. Our strategy is to develop novel combinations that target each of the escape mechanisms used by tumour cells to evade the immune system. Our immuno-oncology pipeline contains molecules that enhance immune response, tumour destruction or immune cell memory and compounds that target the tumour microenvironment.
As a leader in personalised healthcare, we are committed to matching new medicines to the patients most likely to benefit. We combine industry-leading expertise in companion diagnostics with laboratory science in molecular diagnostics, tissue diagnostics, imaging and protein biomarkers. This includes working collaboratively with our external partners to harness break-through technologies across the life-cycle of our medicines.
Emerging drug discovery
Our teams work alongside the world's leading academic and biotech research institutions to stimulate innovation and evaluate emerging technologies. By combining the great science happening in our labs with the best external science, we can accelerate drug discovery and development across our main therapy areas. Today, our teams are working in pioneering fields such as modified RNA and CRISPR genome editing.
Partnering: a way of life
We work alongside scientists at leading institutions to better understand disease, identify potential new drugs and accelerate drug development. We’re also pioneers in creating a more open research environment.
Where science thrives
Our research sites are collaborative, innovative and dynamic environments that allow our scientists to keep pushing the boundaries
Our new facility in Cambridge will bring together our small molecule and biologics research and development activity. It will become our largest centre for oncology research and also house scientists focused on cardiovascular and metabolic diseases, respiratory, inflammation and autoimmune diseases and conditions of the central nervous system.
Our vibrant science facility in Gothenburg is a world-leading centre for research and development in cardiovascular and metabolic diseases, and respiratory, inflammation and autoimmunity. It also houses science teams responsible for all phases and aspects of small molecule drug discovery and development – from initial ideas through to new medicines.
Our Gaithersburg centre is headquarters to MedImmune and our primary location for biologics research and development in the US. It is also home to our Global Medicines Development function and Specialty Products Group. The modern, vibrant, scientific campus employs more than 3,000 experts in our field and is only a short drive from Washington, DC.
Three science units with one shared goal
Discovery and early development: combining the strengths of our 2 autonomous biotech units
IMED Biotech Unit
- SMALL MOLECULES
IMED Biotech Unit
Focuses on scientific advances in small molecules, oligonucleotides and other emerging technologies and drug discovery platforms across our focus areas.Find out more
Explores novel biologics pathways across our focus areas and pioneers innovative research using unparalleled expertise in protein engineering, translational sciences and immunology.Find out more
An exciting pipeline
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
projects in our pipeline
projects progressed to next phase in the last quarter
new molecular entities in our late-stage pipeline
and help us deliver life-changing medicines
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.